問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

National Taiwan University Hospital Hsin-Chu Branch

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Cancer Center

Division of Hematology & Oncology

更新時間：2023-09-19

盧彥伸LU, YEN-SHEN
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

109Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

盧彥伸

List

218Cases

2023-12-01 - 2027-12-31

Phase III

A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

  • Condition/Disease

    ER-positive, HER2-negative advanced or metastatic breast cancer

  • Test Drug

    OP-1250Fulvestrant Sandoz 250mg/5ml Solution for InejctionFulvestrant Lyophilized Injection 250mg "GBC"Anastrozole F.C. Tablets 1mg "Sinphar"Arbreast F.C. Tab. 1mg (Anastrozole)Aromatt 1 (An

Participate Sites
9Sites

Recruiting9Sites

2023-04-01 - 2030-12-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy

  • Condition/Disease

    Breast Cancer

  • Test Drug

    GDC-0077(Inavolisib)Alpelisib(Piqray)Fulvestrant (Faslodex)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2016-04-01 - 2018-12-31

Phase I

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Oraxol

Participate Sites
6Sites

Terminated6Sites

趙大中
Taipei Veterans General Hospital

Division of Radiation Therapy

2017-09-01 - 2021-12-31

Phase I

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Oraxol

Participate Sites
7Sites

Terminated6Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

趙大中
Taipei Veterans General Hospital

Division of Radiation Therapy

2019-10-01 - 2023-02-28

Phase III

A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.

  • Condition/Disease

    Triple-Negative Breast Cancer

  • Test Drug

    Ipatasertib, Atezolizumab, Paclitaxel

Participate Sites
5Sites

Terminated5Sites

2020-08-01 - 2023-06-30

Phase I

A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer

  • Condition/Disease

    Triple-Negative Breast Cancer

  • Test Drug

    Tiragolumab；Atezolizumab

Participate Sites
2Sites

Recruiting2Sites

2021-06-01 - 2031-12-24

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2008-02-01 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-12-01 - 2021-12-31

Phase III

A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

  • Condition/Disease

    TNBC, HR+/HER2- breast cancer

  • Test Drug

    IPATASERTIB

Participate Sites
3Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2016-06-01 - 2021-12-24

Phase III

A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY

  • Condition/Disease

    LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • Test Drug

    TASELISIB and FULVESTRANT

Participate Sites
9Sites

Terminated7Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

1 11 12 13 14 15 22
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB